Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A second chance: new tests aim to catch hidden heart damage in childhood cancer survivors

NCT ID NCT04852965

Diagnosis Sponsor: Queen's University, Belfast Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study investigates whether advanced heart imaging and blood tests can detect early signs of heart damage in adults who received anthracycline chemotherapy as children. Anthracyclines are effective cancer treatments but can increase the risk of cardiomyopathy years later. Current methods often diagnose heart damage too late, when it is irreversible. The study will use echocardiography, strain imaging, MRI, and biomarkers to see if they can predict heart problems earlier, potentially allowing for timely intervention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Advanced heart imaging (echocardiography, strain imaging, MRI, Holter monitoring) and blood biomarkers
What this could lead to
If successful, this could enable earlier detection of heart damage in childhood cancer survivors, allowing timely treatment to prevent irreversible heart failure.
What could go wrong
The study is observational and relatively small, so findings may not apply to all survivors. The techniques and biomarkers may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

103 people

The number who actually took part.

Started

Oct 2021

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients identified by paediatric oncology who have received anthracycline therapy in childhood.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Male and female patients over the age of 18 who have received at least moderate (100mg/m2) anthracycline chemotherapy as a child (\<16 years). Exclusion Criteria: * patients born with complex heart disease * patients who would not be safely able to have a magnetic resonance imaging scan * patients who cannot give consent * patients under the age of 18 or who have had less than a moderate dose of anthracycline

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anthracycline induced cardiotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiomyopathy cardiomyopathy due to anthracyclines Cardiotoxicity Sprains and Strains

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anthracycline induced cardiotoxicity

Contacts and locations

Locations

  • Belfast Health and Social Care Trust

    Belfast, BT9 7AB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.